More recently, a high response rate and good tolerability with no evidence of increased toxicity have been shown with the use of the anti-CD33 immunoconjugate gemtuzumab-ozogamicin plus midostaurin added to standard intensive chemotherapeutic regimens in patients with newly diagnosed FLT3-mutated/CD33+ AML [159]. This evidence concerns the gene CD33 and acute myeloid leukemia.